Compounds > cyc 202
Page last updated: 2024-09-04

cyc 202 and erlotinib

cyc 202 has been researched along with erlotinib in 8 studies

Compound Research Comparison

Studies
(cyc 202)		Trials
(cyc 202)		Recent Studies (post-2010)
(cyc 202)		Studies
(erlotinib)		Trials
(erlotinib)		Recent Studies (post-2010) (erlotinib)
97973932210180

Protein Interaction Comparison

ProteinTaxonomycyc 202 (IC50)erlotinib (IC50)
epidermal growth factor receptor isoform a precursorHomo sapiens (human)0.001
Cyclin-G-associated kinaseHomo sapiens (human)0.474
Tyrosine-protein kinase JAK2Homo sapiens (human)4
Solute carrier organic anion transporter family member 2B1 Homo sapiens (human)0.55
Bile salt export pumpHomo sapiens (human)10
Proto-oncogene tyrosine-protein kinase SrcGallus gallus (chicken)0.99
Epidermal growth factor receptorHomo sapiens (human)0.5294
Receptor tyrosine-protein kinase erbB-2Homo sapiens (human)0.7171
Cytochrome P450 3A4Homo sapiens (human)0.016
Platelet-derived growth factor receptor betaHomo sapiens (human)0.0122
Serine/threonine-protein kinase B-rafHomo sapiens (human)0.06
Corticosteroid 11-beta-dehydrogenase isozyme 1 Rattus norvegicus (Norway rat)0.03
Platelet-derived growth factor receptor alphaHomo sapiens (human)8.12
Vascular endothelial growth factor receptor 1 Homo sapiens (human)0.25
Receptor tyrosine-protein kinase erbB-3Homo sapiens (human)0.2586
Sodium-dependent dopamine transporterRattus norvegicus (Norway rat)0.369
Cyclin-dependent kinase 2Homo sapiens (human)1.14
Adenosine receptor A1Rattus norvegicus (Norway rat)0.0063
Serine/threonine-protein kinase B-raf Mus musculus (house mouse)0.06
Cytochrome P450 2C19Homo sapiens (human)0.087
Vascular endothelial growth factor receptor 3Homo sapiens (human)0.25
Vascular endothelial growth factor receptor 2Homo sapiens (human)0.8349
D(1A) dopamine receptorSus scrofa (pig)0.3
Fatty-acid amide hydrolase 1Rattus norvegicus (Norway rat)0.0095
Synaptic vesicular amine transporterRattus norvegicus (Norway rat)0.001
Focal adhesion kinase 1Homo sapiens (human)7.4
Receptor tyrosine-protein kinase erbB-4Homo sapiens (human)0.6925
Canalicular multispecific organic anion transporter 1Homo sapiens (human)10
Alpha-1A adrenergic receptor Sus scrofa (pig)0.3
Serine/threonine-protein kinase TBK1Homo sapiens (human)2.2
Broad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)0.13

Research

Studies (8)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (37.50)29.6817
2010's3 (37.50)24.3611
2020's2 (25.00)2.80

Authors

AuthorsStudies
Atteridge, CE; Azimioara, MD; Benedetti, MG; Biggs, WH; Carter, TA; Ciceri, P; Edeen, PT; Fabian, MA; Floyd, M; Ford, JM; Galvin, M; Gerlach, JL; Grotzfeld, RM; Herrgard, S; Insko, DE; Insko, MA; Lai, AG; Lélias, JM; Lockhart, DJ; Mehta, SA; Milanov, ZV; Patel, HK; Treiber, DK; Velasco, AM; Wodicka, LM; Zarrinkar, PP1
Bullock, AN; Fedorov, O; Knapp, S; Marsden, B; Müller, S; Pogacic, V; Rellos, P; Schwaller, J; Sundström, M1
Atteridge, CE; Campbell, BT; Chan, KW; Ciceri, P; Davis, MI; Edeen, PT; Faraoni, R; Floyd, M; Gallant, P; Herrgard, S; Hunt, JP; Karaman, MW; Lockhart, DJ; Milanov, ZV; Morrison, MJ; Pallares, G; Patel, HK; Pritchard, S; Treiber, DK; Wodicka, LM; Zarrinkar, PP1
Russu, WA; Shallal, HM1
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ1
Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP1
Bharate, SB; Raghuvanshi, R1
Caballero, E; García-Cárceles, J; Gil, C; Martínez, A1

Reviews

1 review(s) available for cyc 202 and erlotinib

ArticleYear
Kinase Inhibitors as Underexplored Antiviral Agents.
    Journal of medicinal chemistry, 2022, 01-27, Volume: 65, Issue:2

    Topics: Animals; Antiviral Agents; Drug Repositioning; Humans; Protein Kinase Inhibitors; Virus Diseases; Viruses

2022

Other Studies

7 other study(ies) available for cyc 202 and erlotinib

ArticleYear
A small molecule-kinase interaction map for clinical kinase inhibitors.
    Nature biotechnology, 2005, Volume: 23, Issue:3

    Topics: Benzamides; Drug Design; Escherichia coli; Escherichia coli Proteins; Imatinib Mesylate; Microchemistry; Pharmaceutical Preparations; Piperazines; Protein Binding; Protein Interaction Mapping; Protein Kinase Inhibitors; Pyrimidines

2005
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
    Proceedings of the National Academy of Sciences of the United States of America, 2007, Dec-18, Volume: 104, Issue:51

    Topics: Amino Acid Sequence; Binding Sites; Clinical Trials as Topic; Drug Evaluation, Preclinical; Enzyme Stability; Humans; Molecular Sequence Data; Phylogeny; Protein Array Analysis; Protein Conformation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases

2007
A quantitative analysis of kinase inhibitor selectivity.
    Nature biotechnology, 2008, Volume: 26, Issue:1

    Topics: Binding Sites; Enzyme Activation; Humans; Phosphotransferases; Protein Binding; Protein Interaction Mapping; Protein Kinase Inhibitors; Proteome; Quantitative Structure-Activity Relationship

2008
Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.
    European journal of medicinal chemistry, 2011, Volume: 46, Issue:6

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Molecular Structure; Piperazines; Protein Kinase Inhibitors; Protein Kinases; Pyrimidines; Stereoisomerism; Structure-Activity Relationship

2011
Identification of potent Yes1 kinase inhibitors using a library screening approach.
    Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

    Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013
The target landscape of clinical kinase drugs.
    Science (New York, N.Y.), 2017, 12-01, Volume: 358, Issue:6367

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays

2017
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
    Journal of medicinal chemistry, 2022, 01-27, Volume: 65, Issue:2

    Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Drug Approval; Drug Repositioning; High-Throughput Screening Assays; Humans; Protein Kinase Inhibitors; SARS-CoV-2; United States; United States Food and Drug Administration; Virus Diseases

2022